Linifanib
Linifanib (pronounced li-ni-fa-nib) is a type of antineoplastic agent that is used in the treatment of certain types of cancer. It is a small molecule inhibitor of receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR).
Etymology
The name "Linifanib" is derived from the Latin word "linum" meaning flax, and "fanib" which is an acronym for "Farnesyltransferase And Neuroblastoma Inhibitor B". This is in reference to the drug's ability to inhibit the growth of cancer cells.
Pharmacology
Linifanib works by inhibiting the activity of certain proteins that are involved in the growth and spread of cancer cells. These proteins, known as receptor tyrosine kinases, are involved in the signaling pathways that regulate cell growth, proliferation, and survival. By blocking these proteins, linifanib can help to slow down or stop the growth of cancer cells.
Clinical Use
Linifanib is currently being studied in clinical trials for the treatment of various types of cancer, including hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC).
Side Effects
Like all chemotherapy drugs, linifanib can cause side effects. These may include nausea, vomiting, diarrhea, and fatigue. More serious side effects can include liver damage, high blood pressure, and bleeding.
See Also
- Antineoplastic agent
- Receptor tyrosine kinase
- Vascular endothelial growth factor receptor
- Platelet-derived growth factor receptor
- Hepatocellular carcinoma
- Renal cell carcinoma
- Non-small cell lung cancer
External links
- Medical encyclopedia article on Linifanib
- Wikipedia's article - Linifanib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski